Skip to main content
DrugPrice

Trogarzo

Ibalizumab

Generic availableHIVby Theratechnologies
$22,250.00
avg cost per claim
+8.4% year-over-year
$89.0M
Medicare Spending
4,000
Total Claims
480
Beneficiaries
$185,417.00
Annual Cost/Patient

Why Trogarzo Costs $22,250.00 Per Claim

Trogarzo (Ibalizumab) is used to treat hiv. According to CMS Medicare Part D spending data, the program spent $89.0M on this drug, covering 480 beneficiaries across 4,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Ibalizumab or talk to their doctor about therapeutic alternatives that may cost less.

Price Breakdown

Avg cost per claim (30-day)$22,250.00
Avg annual cost per patient$185,417.00
Total Medicare spending$89.0M
Total claims4,000
Beneficiaries480

Drug Details

Brand Name
Trogarzo
Generic Name
Ibalizumab
Active Ingredient
Ibalizumab
Manufacturer
Theratechnologies
Dosage Form
N/A
Route
N/A
Condition
HIV
FDA Application
BLA125057

Frequently Asked Questions

Trogarzo (Ibalizumab) costs an average of $22,250.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $185,417.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Yes, a generic version of Trogarzo (Ibalizumab) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Ibalizumab.

Medicare Part D spent $89.0M on Trogarzo, covering 480 beneficiaries across 4,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Ibalizumab, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.